

Estimate change	↔
TP change	↔
Rating change	↔

Bloomberg	CLGT IN
Equity Shares (m)	272
M.Cap.(INRb)/(USD\$)	622 / 7.1
52-Week Range (INR)	3360 / 2151
1, 6, 12 Rel. Per (%)	-5/-21/-37
12M Avg Val (INR M)	1402

### Financials & Valuations (INR b)

Y/E March	2026E	2027E	2028E
Sales	61.6	67.1	72.1
Sales Gr. (%)	2.1	8.9	7.3
EBITDA	19.8	22.0	23.9
EBITDA Margin (%)	32.1	32.7	33.1
Adj. PAT	14.1	15.7	17.1
Adj. EPS (INR)	51.9	57.8	63.0
EPS Gr. (%)	1.0	11.5	8.9
BV/Sh.(INR)	58.1	57.9	59.8

### Ratios

RoE (%)	87.0	99.7	107.0
RoCE (%)	86.7	99.4	106.6
Payout (%)	106.0	100.3	96.9

### Valuation

P/E (x)	44.3	39.8	36.5
P/BV (x)	39.6	39.7	38.4
EV/EBITDA (x)	31.1	28.0	25.8
Div. Yield (%)	2.4	2.5	2.7

### Shareholding Pattern (%)

As On	Sep-25	Jun-25	Sep-24
Promoter	51.0	51.0	51.0
DII	12.2	9.6	5.8
FII	17.2	20.4	24.9
Others	19.6	19.0	18.2

FII includes depository receipts

**CMP: INR2,287      TP: INR2,850 (+25%)      BUY**

## Muted 2Q print; watchful for growth recovery ahead

- Colgate's (CLGT) 2QFY26 performance remained weak as its revenue fell 6% YoY to INR15.2b (in line) on a high base of 10% growth and due to the impact of GST-led transition (trade disruptions). We believe that volume is likely to have declined ~5% (in line). CLGT continued to focus on premiumization and investing in its brands, resulting in the premium portfolio delivering better revenue growth.
- Gross margin expanded 100bp YoY and 60bp QoQ to 69.5% (est. 67.9%). EBITDA margin was flat YoY at 30.6% (est. 29.8%). EBITDA declined by 6% YoY to INR4.7b.
- CLGT's performance has been relatively weak over the past 4-5 quarters, marked by muted revenue growth and margin contraction. However, following the reduction in the GST rate on the entire oral care portfolio from 18% to 5%, which benefitted nearly 95% of the company's portfolio, we believe CLGT is well positioned for a recovery in the coming quarters, supported by improving demand trends.
- We recently upgraded CLGT from Neutral to BUY following the rollout of GST 2.0 ([link](#)) and ~30% stock correction over the past 12 months. The stock is trading at a comfortable valuation of 40x P/E for FY27. Maintain BUY with a TP of INR2,850 (45x Sep'27).

## Weak performance; but largely in line

- Volumes decline in mid-single digit:** Revenue declined 6% YoY to INR15.2b (est. INR15.3b) on a high base of 10% growth and the impact of GST-led transitions.
- Sustains healthy margins** - Gross margins expanded by 100bp YoY to 69.5% (est. 67.9%). Gross profit was down 5% YoY. Employee expenses were flat YoY, while ad spends and other expenses were down by 7% and 2%, respectively. EBITDA contracted by 6% YoY to INR4.7b (est. INR4.5b). EBITDA margin was flat YoY at 30.6% (est. 29.8%).
- Decline in profitability:** PBT declined 7% YoY to INR4.4b (est. INR4.3b). APAT was down 8% YoY at INR3.3b (est. INR3.2b).
- In 1HFY26, net sales, EBITDA and APAT fell 5%, 9% and 10%, respectively.
- The company announced its first interim dividend of INR24 per share.

## Key highlights from management commentary

- GST rates on the oral care portfolio were reduced from 18% to 5%, a move welcomed as supportive of consumer confidence and oral health awareness.
- Lower prices were promptly passed on to consumers in collaboration with trade partners.
- The quarter saw temporary disruption for distributors and retailers due to the GST rate change, impacting the company's near-term performance.

**Naveen Trivedi – Research Analyst** (Naveen.Trivedi@MotilalOswal.com)

**Research Analyst: Amey Tiwari** (Amey.Tiwari@MotilalOswal.com) | **Tanu Jindal** (Tanu.Jindal@MotilalOswal.com)

**Investors are advised to refer through important disclosures made at the last page of the Research Report.**

MotilalOswal research is available on [www.motilaloswal.com/Institutional-Equities](http://www.motilaloswal.com/Institutional-Equities), Bloomberg, Thomson Reuters, Factset and S&P Capital.

- 1HFY26 has a high double-digit growth base, with a gradual recovery expected in the second half.
- Margins remained resilient, supported by continued focus on its “Funding The Growth” program.
- The company maintained strong premium portfolio momentum, led by Colgate Visible White Purple.
- Palmolive’s new *Moments* body wash range was launched, featuring 100% natural extracts and patented fragrance technology.
- The “CAVITY-PROOF” campaign under Colgate Strong Teeth reinforced the brand’s advanced Arginine + Calcium Boost technology for 24-hour anti-cavity protection.

**Valuation and view**

- We largely maintain our EPS estimates for FY26/FY27.
- The company’s performance has been relatively weak over the past 3-4 quarters, marked by muted revenue growth and margin contraction. However, following the implementation of GST 2.0, which reduced the GST rate on toothpaste from 18% to 5%, benefiting nearly 95% of the company’s portfolio, we believe CLGT is well-positioned for a recovery in the coming quarters, supported by improving demand trends.
- CLGT remains focused on driving sustainable revenue growth through multiple levers — 1) launching science-backed, premium innovations to enhance realizations, 2) expanding category reach through increased marketing and consumer education, 3) deepening rural penetration to drive frequency and new user addition, and 4) broadening its presence in personal care to reduce dependence on the slower-growing oral care category.
- The stock has corrected ~30% over the past 12 months and is trading at a comfortable valuation of 45x and 40x P/E for FY26 and FY27, respectively. We maintain BUY rating on the stock with a TP of INR2,850 (45x Sep’27).


**Quarterly Performance**

Y/E March	(INR m)											
	FY25				FY26E				FY25	FY26E	FY26	Var.
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			2QE	(%)
<b>Volume Gr %</b>	7.0	8.0	4.0	0.0	-3.0	-5.0	6.0	8.0	4.8	1.5	-5.0	
<b>Net Sales (inclgd. OOI)</b>	14,967	16,191	14,618	14,625	14,341	15,195	15,809	16,301	60,402	61,645	15,252	-0.4%
YoY change (%)	13.1	10.1	4.7	-1.8	-4.2	-6.2	8.1	11.5	6.3	2.1	-5.8	
<b>Gross Profit</b>	10,574	11,098	10,220	10,327	9,884	10,553	11,066	11,340	42,219	42,843	10,356	1.9%
Gross margin (%)	70.6	68.5	69.9	70.6	68.9	69.5	70.0	69.6	69.9	69.5	67.9	
<b>EBITDA</b>	5,083	4,974	4,544	4,980	4,526	4,654	4,980	5,628	19,581	19,788	4,545	2.4%
Margins (%)	34.0	30.7	31.1	34.1	31.6	30.6	31.5	34.5	32.4	32.1	29.8	
YoY growth (%)	21.6	3.2	-3.0	-6.4	-11.0	-6.4	9.6	13.0	3.0	1.1	-8.6	
Depreciation	415	417	411	384	375	372	448	570	1,627	1,766	444	
Interest	10	12	11	11	10	10	12	15	43	48	13	
Financial other Income	234	195	204	191	179	150	220	328	824	878	211	
<b>PBT</b>	4,893	4,740	4,325	4,776	4,320	4,423	4,740	5,371	18,734	18,853	4,299	2.9%
Tax	1,253	1,354	1,097	1,226	1,113	1,148	1,194	1,290	4,930	4,745	1,083	
Rate (%)	25.6	28.6	25.4	25.7	25.8	25.9	25.2	24.0	26.3	25.2	25.2	3.0%
<b>Adj PAT</b>	3,640	3,555	3,228	3,550	3,206	3,275	3,545	4,081	13,973	14,108	3,215	1.9%
YoY change (%)	26.2	4.6	-2.2	-6.5	-11.9	-7.9	9.8	15.0	4.4	1.0	-9.6	
<b>Reported PAT</b>	3,640	3,951	3,228	3,550	3,206	3,275	3,545	4,081	14,368	14,108	3,215	

E: MOFSL Estimates


## Key exhibits

**Exhibit 1: Toothpaste volume would have declined in a mid-single digit in 2QFY26**




Source: MOFSL

**Exhibit 2: Revenue declined 6% YoY to INR15.2b in 2QFY26**




Sources: Company reports, MOFSL

**Exhibit 3: Gross margin expanded 100bp YoY to 69.5%**




Sources: Company reports, MOFSL

**Exhibit 4: EBITDA margin largely flat YoY at 30.6%**



Sources: Company reports, MOFSL

**Exhibit 5: EBITDA fell 6% YoY to INR4.7b in 2QFY26**




Sources: Company reports, MOFSL

**Exhibit 6: We maintain our EPS estimates for FY26/FY27**

	Old		New		Change (%)	
	FY26E	FY27E	FY26E	FY27E	FY26E	FY27E
<b>Sales</b>	62,003	67,533	61,645	67,144	(0.6)	(0.6)
<b>EBITDA</b>	19,717	22,083	19,788	21,956	0.4	(0.6)
<b>PAT</b>	14,054	15,822	14,108	15,727	0.4	(0.6)


Source: MOFSL

**Exhibit 7: P/E ratio (x) for CLGT**



Sources: Company reports, MOFSL

**Exhibit 8: P/E ratio (x) for the Consumer sector**



Sources: Company reports, MOFSL

## Financials and valuations

Income Statement								(INR m)		
Y/E March	2019	2020	2021	2022	2023	2024	2025	2026E	2027E	2028E
<b>Net Sales</b>	<b>44,624</b>	<b>45,251</b>	<b>48,412</b>	<b>50,998</b>	<b>52,262</b>	<b>56,804</b>	<b>60,402</b>	<b>61,645</b>	<b>67,144</b>	<b>72,068</b>
Change (%)	6.6	1.4	7.0	5.3	2.5	8.7	6.3	2.1	8.9	7.3
COGS	15,586	15,729	15,494	16,675	17,942	17,230	18,183	18,802	20,143	21,260
<b>Gross Profit</b>	<b>29,039</b>	<b>29,522</b>	<b>32,919</b>	<b>34,323</b>	<b>34,320</b>	<b>39,574</b>	<b>42,219</b>	<b>42,843</b>	<b>47,001</b>	<b>50,808</b>
Gross Margin (%)	65.1	65.2	68.0	67.3	65.7	69.7	69.9	69.5	70.0	70.5
<b>EBITDA</b>	<b>12,361</b>	<b>12,017</b>	<b>15,096</b>	<b>15,660</b>	<b>15,470</b>	<b>19,008</b>	<b>19,581</b>	<b>19,788</b>	<b>21,956</b>	<b>23,854</b>
Change (%)	11.1	-2.8	25.6	3.7	-1.2	22.9	3.0	1.1	11.0	8.6
Margin (%)	27.7	26.6	31.2	30.7	29.6	33.5	32.4	32.1	32.7	33.1
Depreciation	1,592	1,979	1,825	1,773	1,748	1,715	1,627	1,766	1,803	1,858
Int. and Fin. Charges	25	96	73	59	49	50	43	48	52	57
Financial Other Income	377	492	304	263	536	765	824	878	916	944
<b>Profit before Taxes</b>	<b>11,121</b>	<b>10,434</b>	<b>13,502</b>	<b>14,090</b>	<b>14,209</b>	<b>18,008</b>	<b>18,734</b>	<b>18,853</b>	<b>21,016</b>	<b>22,883</b>
Change (%)	11.8	-6.2	29.4	4.4	0.8	26.7	4.0	0.6	11.5	8.9
Margin (%)	24.9	23.1	27.9	27.6	27.2	31.7	31.0	30.6	31.3	31.8
Tax	3,670	2,269	3,257	3,448	3,724	4,937	4,949	4,745	5,290	5,760
Deferred Tax	0	-31	-109	-141	-99	-360	-19	0	0	0
Tax Rate (%)	33.0	21.5	23.3	23.5	25.5	25.4	26.3	25.2	25.2	25.2
<b>Adjusted PAT</b>	<b>7,502</b>	<b>8,165</b>	<b>10,354</b>	<b>10,783</b>	<b>10,555</b>	<b>13,383</b>	<b>13,973</b>	<b>14,108</b>	<b>15,727</b>	<b>17,123</b>
Change (%)	9.5	8.8	26.8	4.1	-2.1	26.8	4.4	1.0	11.5	8.9
Margin (%)	16.8	18.0	21.4	21.1	20.2	23.6	23.1	22.9	23.4	23.8
Non-rec. (Exp)/Income	254	0	0	0	-83	-146	395	0	0	0
<b>Reported PAT</b>	<b>7,756</b>	<b>8,165</b>	<b>10,354</b>	<b>10,783</b>	<b>10,472</b>	<b>13,237</b>	<b>14,368</b>	<b>14,108</b>	<b>15,727</b>	<b>17,123</b>

Balance Sheet								(INR m)		
Y/E March	2019	2020	2021	2022	2023	2024	2025	2026E	2027E	2028E
Share Capital	272	272	272	272	272	272	272	272	272	272
Reserves	14,196	15,670	11,387	17,075	16,892	18,472	16,373	15,520	15,471	16,002
<b>Net Worth</b>	<b>14,468</b>	<b>15,942</b>	<b>11,659</b>	<b>17,347</b>	<b>17,164</b>	<b>18,744</b>	<b>16,645</b>	<b>15,792</b>	<b>15,743</b>	<b>16,274</b>
Loans	978	1,520	1,102	847	820	828	769	769	769	769
Deferred Liability	309	50	-48	-173	-288	-648	-680	-680	-680	-680
<b>Capital Employed</b>	<b>15,754</b>	<b>17,512</b>	<b>12,713</b>	<b>18,021</b>	<b>17,695</b>	<b>18,924</b>	<b>16,735</b>	<b>15,882</b>	<b>15,833</b>	<b>16,364</b>
Gross Block	21,077	22,182	19,831	20,504	21,240	22,278	23,729	25,229	26,729	28,229
Less: Accum. Depn.	-9,169	-10,953	-9,184	-10,874	-12,622	-14,337	-15,964	-17,730	-19,533	-21,391
<b>Net Fixed Assets</b>	<b>11,909</b>	<b>11,229</b>	<b>10,647</b>	<b>9,630</b>	<b>8,618</b>	<b>7,941</b>	<b>7,765</b>	<b>7,499</b>	<b>7,196</b>	<b>6,838</b>
Capital WIP	1,987	1,900	1,449	1,218	1,141	1,103	384	384	384	384
Investments	312	186	186	0	0	0	0	0	0	0
<b>Curr. Assets, L&amp;A</b>	<b>12,058</b>	<b>12,725</b>	<b>16,611</b>	<b>17,997</b>	<b>18,783</b>	<b>22,274</b>	<b>21,357</b>	<b>21,206</b>	<b>22,543</b>	<b>24,449</b>
Inventory	2,486	2,969	3,358	3,572	3,355	2,964	3,773	3,879	4,230	4,552
Account Receivables	2,098	1,326	1,171	2,247	1,574	1,674	2,263	2,309	2,515	2,699
Cash & Bank	3,994	4,213	8,676	7,547	9,230	13,738	10,951	10,504	10,876	11,893
Others	3,481	4,217	3,405	4,631	4,625	3,898	4,371	4,513	4,923	5,305
<b>Curr. Liab. and Prov.</b>	<b>10,511</b>	<b>8,528</b>	<b>16,179</b>	<b>10,825</b>	<b>10,846</b>	<b>12,394</b>	<b>12,771</b>	<b>13,206</b>	<b>14,291</b>	<b>15,307</b>
Account Payables	6,132	6,125	7,604	7,714	7,611	8,819	9,208	9,442	10,193	10,875
Other Liabilities	3,740	1,798	7,765	2,271	1,953	2,174	2,079	2,131	2,301	2,455
Provisions	639	605	810	840	1,282	1,401	1,485	1,633	1,797	1,976
<b>Net Current Assets</b>	<b>1,547</b>	<b>4,197</b>	<b>431</b>	<b>7,173</b>	<b>7,936</b>	<b>9,881</b>	<b>8,586</b>	<b>7,999</b>	<b>8,253</b>	<b>9,142</b>
<b>Application of Funds</b>	<b>15,754</b>	<b>17,512</b>	<b>12,713</b>	<b>18,021</b>	<b>17,695</b>	<b>18,924</b>	<b>16,735</b>	<b>15,882</b>	<b>15,833</b>	<b>16,364</b>

E: MOFSL Estimates

## Financials and valuations

### Ratios

Y/E March	2019	2020	2021	2022	2023	2024	2025	2026E	2027E	2028E
<b>Basic (INR)</b>										
<b>EPS</b>	<b>27.6</b>	<b>30.0</b>	<b>38.1</b>	<b>39.6</b>	<b>38.8</b>	<b>49.2</b>	<b>51.4</b>	<b>51.9</b>	<b>57.8</b>	<b>63.0</b>
Cash EPS	33.4	37.3	44.8	46.2	45.2	55.5	57.4	58.4	64.4	69.8
BV/Share	53.2	58.6	42.9	63.8	63.1	68.9	61.2	58.1	57.9	59.8
DPS	16.0	28.0	38.0	40.0	39.0	58.0	51.0	55.0	58.0	61.0
Payout %	58.1	93.3	99.8	100.9	100.5	117.9	99.3	106.0	100.3	96.9
<b>Valuation (x)</b>										
P/E	83.5	76.7	60.4	58.0	59.3	46.7	44.8	44.3	39.8	36.5
Cash P/E	68.8	61.7	51.4	49.8	50.9	41.4	40.1	39.4	35.7	33.0
EV/Sales	14.0	13.8	12.8	12.1	11.8	10.8	10.2	10.0	9.2	8.5
EV/EBITDA	50.4	51.9	40.9	39.5	39.9	32.2	31.4	31.1	28.0	25.8
P/BV	43.3	39.3	53.7	36.1	36.4	33.4	37.6	39.6	39.7	38.4
Dividend Yield (%)	0.7	1.2	1.7	1.7	1.7	2.5	2.2	2.4	2.5	2.7
<b>Return Ratios (%)</b>										
RoE	50.5	53.7	75.0	74.4	61.2	74.5	79.0	87.0	99.7	107.0
RoCE	47.3	49.7	68.9	70.5	59.5	73.6	77.6	86.7	99.4	106.6
<b>Working Capital Ratios</b>										
Debtor (Days)	17	11	9	16	11	11	14	14	14	14
Asset Turnover (x)	3.3	2.9	4.4	3.0	3.2	3.2	3.7	4.0	4.3	4.5
<b>Leverage Ratio</b>										
Debt/Equity (x)	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0

### Cash Flow Statement

(INR m)

Y/E March	2019	2020	2021	2022	2023	2024	2025	2026E	2027E	2028E
OP/(loss) before Tax	11,120	10,434	13,502	14,090	14,209	17,813	19,298	18,853	21,016	22,883
Depreciation	1,592	1,979	1,825	1,773	1,748	1,715	1,627	1,766	1,803	1,858
Int./Div. Received	53	-96	35	105	68	-630	-590	0	0	0
Interest Paid	-273	-158	-131	-158	-364	50	43	48	52	57
Direct Taxes Paid	-4,144	-3,213	-3,584	-3,699	-3,809	-4,686	-5,620	-4,745	-5,290	-5,760
(Incr)/Decr in WC	1,494	-35	-3,826	4,151	-89	-2,272	-815	218	457	432
<b>CF from Operations</b>	<b>9,842</b>	<b>8,911</b>	<b>7,823</b>	<b>16,261</b>	<b>11,763</b>	<b>11,990</b>	<b>13,945</b>	<b>16,138</b>	<b>18,039</b>	<b>19,471</b>
(Incr)/Decr in FA	-1,042	-604	-573	-495	-695	-755	-714	-1,500	-1,500	-1,500
<b>Free Cash Flow</b>	<b>8,800</b>	<b>8,307</b>	<b>7,249</b>	<b>15,766</b>	<b>11,068</b>	<b>11,234</b>	<b>13,231</b>	<b>14,638</b>	<b>16,539</b>	<b>17,971</b>
(Pur)/Sale of Investments	0	7	1,060	-812	221	828	548	0	0	0
Others	-1,221	419	5,954	-5,178	1,262	4,398	148	-75	-336	-301
<b>CF from Invest.</b>	<b>-2,263</b>	<b>-177</b>	<b>6,440</b>	<b>-6,485</b>	<b>788</b>	<b>4,471</b>	<b>-18</b>	<b>-1,575</b>	<b>-1,836</b>	<b>-1,801</b>
Change in Equity	0	0	0	0	0	0	0	0	0	0
(Incr)/Decr in Debt	0	0	0	0	0	0	0	0	0	0
Dividend Paid	-7,916	-8,433	-9,211	-10,572	-10,575	-11,670	-16,262	-14,960	-15,776	-16,592
Others	-231	-81	-353	-334	-293	-282	-451	-51	-56	-61
<b>CF from Fin. Activity</b>	<b>-8,147</b>	<b>-8,514</b>	<b>-9,565</b>	<b>-10,906</b>	<b>-10,867</b>	<b>-11,953</b>	<b>-16,713</b>	<b>-15,011</b>	<b>-15,832</b>	<b>-16,653</b>
<b>Incr/Decr of Cash</b>	<b>-568</b>	<b>219</b>	<b>4,698</b>	<b>-1,129</b>	<b>1,683</b>	<b>4,508</b>	<b>-2,787</b>	<b>-447</b>	<b>371</b>	<b>1,017</b>
Add: Opening Balance	4,562	3,994	3,978	8,676	7,547	9,230	13,738	10,951	10,504	10,876
<b>Closing Balance</b>	<b>3,994</b>	<b>4,213</b>	<b>8,676</b>	<b>7,547</b>	<b>9,230</b>	<b>13,738</b>	<b>10,951</b>	<b>10,504</b>	<b>10,876</b>	<b>11,893</b>

E: MOFSL Estimates

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.



Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

\*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

**Disclosures**

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412 and BSE enlistment no. 5028. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on [www.motilaloswal.com](http://www.motilaloswal.com). MOFSL is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products and is a member of Association of Portfolio Managers in India (APMI) for distribution of PMS products. Details of associate entities of Motilal Oswal Financial Services Ltd. are available on the website at <http://online-reports.motilaloswal.com/Dormant/documents/Associate%20Details.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at [www.nseindia.com](http://www.nseindia.com), [www.bseindia.com](http://www.bseindia.com). Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

**Regional Disclosures (outside India)**

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

**For Hong Kong:**

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

**For U.S.**

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

**For Singapore**

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL .

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to [grievances@motilaloswal.com](mailto:grievances@motilaloswal.com).

Nainesh Rajani

Email: [nainesh.rajani@motilaloswal.com](mailto:nainesh.rajani@motilaloswal.com)

Contact: (+65) 8328 0276

**Specific Disclosures**

1. Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies).  
MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: No.  
Nature of Financial interest is holding equity shares or derivatives of the subject company
2. Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.  
MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report:No
3. Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.  
MOFSL may have received compensation from the subject company(ies) in the past 12 months.
4. Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.  
MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
5. Research Analyst has not served as an officer, director or employee of subject company(ies).
6. MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
7. MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
8. MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
9. MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
10. MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

**Analyst Certification**

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

**Terms & Conditions:**

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

**Disclaimer:**

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI, enlistment as RA with Exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com.

Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal,

Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com
Mr. Neeraj Agarwal	022 40548085	na@motilaloswal.com
Mr. Siddhartha Khemka	022 50362452	po.research@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH00000412, BSE enlistment no. 5028 . AMFI: ARN .: 146822. IRDA Corporate Agent – CA0579, APMI: APRN00233. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.